In 36 NSCLC patients we detected IFN-γ-producing CD8+ and CD4+ T cells responsive to the all tested antigens (Fig 4F) which support our findings that our DC-based HHP lung cancer vaccine is fully competent to induce anti-tumor T cell responses in NSCLC patients. The gene discussed is CD4; the disease is non-small cell lung carcinoma.